Welcome to our dedicated page for Genenta Science Spa SEC filings (Ticker: GNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genenta Science S.p.A. (NASDAQ: GNTA) SEC filings page on Stock Titan brings together the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a foreign private issuer and clinical-stage immuno-oncology company, Genenta reports key information about its Temferon™ development programs, financing activities, and governance through Form 6-K and related filings.
In these filings, investors can find unaudited consolidated financial statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations, which outline Genenta’s cash resources, operating expenses, and funding runway in relation to its solid tumor clinical programs. Other 6-Ks describe registered direct offerings of American Depositary Shares under a shelf registration statement on Form F-3, including purchase agreements, placement agency agreements, and use-of-proceeds language.
Genenta also uses SEC filings to document a Mandatory Convertible Bond financing with ENEA Tech and Biomedical, amendments to its by-laws, changes in the size and composition of its Board of Directors, and executive leadership transitions such as the appointment or resignation of a Chief Medical Officer. Shareholder meeting notices and outcomes, including approvals of statutory financial statements and director appointments, are similarly detailed in these reports.
Through Stock Titan, users can access Genenta’s 6-Ks, registration statements, prospectus supplements, and related exhibits as they are made available on EDGAR, along with AI-powered summaries that explain the practical meaning of each document. This includes highlighting where Genenta discusses its Temferon clinical trials in glioblastoma multiforme and metastatic renal cell carcinoma, capital structure changes, and material agreements with manufacturing partners. For those monitoring insider holdings, the SEC database also provides ownership and transaction reports that complement the company’s own ownership updates.
Use this page to quickly review GNTA’s latest SEC filings, compare new disclosures with prior reports, and understand how regulatory documents reflect the evolution of Genenta’s immuno-oncology platform and corporate strategy.
Genenta Science S.p.A. director Sharei Armon has reported initial holdings consisting solely of stock options linked to American Depositary Shares (ADSs). These include options over 20,163 ADSs at an exercise price of $3.0800 per share, which became fully vested and exercisable on July 1, 2024.
Armon also holds options over 20,000 ADSs at an exercise price of $4.3600, vesting in equal monthly installments over one year beginning June 4, 2025, and options over 10,000 ADSs at $1.4800, vesting monthly over one year beginning December 18, 2025. Each ADS represents one ordinary share of Genenta.
Genenta Science S.p.A. director Miguel Maria Mutti has filed an initial Form 3, detailing his equity position in the company. The filing shows direct ownership of 33,333 American Depositary Shares (ADSs), with no ordinary shares reported directly held. According to the disclosure, each ADS represents one ordinary share of Genenta, so this filing establishes Mutti’s baseline stake rather than recording any new purchase or sale.
Genenta Science S.p.A. director and executive officer Francesco Galimi reported his initial holdings as a new insider. The filing shows stock options over 20,000 ADSs at an exercise price of $4.36 per ADS, expiring on June 4, 2035, vesting in equal monthly installments over one year beginning June 4, 2025. It also shows stock options over 27,110 ADSs at an exercise price of $2.57 per ADS, expiring on November 1, 2035, which vested in three equal monthly installments beginning November 1, 2025 and are now fully vested. The filing lists no directly held ordinary shares or ADSs.
Genenta Science S.p.A. filed an initial ownership report for Chief Executive Officer and 10% owner Pierluigi Paracchi, showing his current equity position rather than any new trades. He reports direct ownership of 2,275,516 Ordinary Shares and 27,000 American Depositary Shares (ADSs), with each ADS representing one ordinary share.
The filing also lists several stock option grants over ADSs: options over 120,000 ADSs at an exercise price of $3.08 expiring in 2034, 80,000 ADSs at $4.36 expiring in 2035, and 180,000 ADSs at $1.48 expiring in 2035. According to the notes, these options vest in equal monthly installments over three years beginning on July 1, 2024, June 4, 2025, and December 18, 2025, respectively, indicating a multi-year equity incentive structure aligned with his leadership role.
Genenta Science S.p.A. Chief Financial Officer Richard B. Slansky filed an initial ownership report showing a mix of stock options, ordinary shares and American Depositary Shares. He holds several option grants over ADSs with exercise prices of $4.76, $3.08, $4.36 and $1.48, vesting over multi‑year schedules and expiring between 2032 and 2035. In addition, he directly owns 19,947 ordinary shares and 2,200 ADSs, with each ADS representing one ordinary share.
GNTA is amending its at-the-market program so it may issue and sell American Depositary Shares with aggregate sales proceeds of up to $26,441,569 from time to time under an existing Sales Agreement with Virtu Americas LLC and Rodman & Renshaw LLC. The prior authorization allowed up to $29,696,999, of which ADSs generating $3,255,430 in gross proceeds have already been sold. Net proceeds from any future sales are intended for general corporate purposes, working capital and potential acquisitions or investments. The ADSs trade on Nasdaq under the symbol GNTA, with a last reported sale price of $1.30 per ADS on January 26, 2026.
Genenta Science S.p.A. investor Pierluigi Paracchi reports a 9.8% ownership stake in the company’s ordinary shares as of January 25, 2026. He beneficially owns 2,302,516 ordinary shares, including 27,000 American depository shares, with sole voting and dispositive power over the entire amount and no shared power.
The percentage is calculated based on 23,432,183 Genenta ordinary shares outstanding as of the same date, indicating that Paracchi remains a significant but non‑controlling shareholder.
Genenta Science S.p.A. outlines a major strategic shift alongside governance and legal updates. The company plans to change its corporate name to Saentra Forge S.p.A. and its Nasdaq ticker to SAEN, subject to shareholder approval at an extraordinary meeting scheduled for March 25–26, 2026.
The business intends to expand from its existing Temferon-focused biotech activities into acting as a biotech, defense, aerospace and national security industrial consolidator under Italy’s Golden Power regime. As part of this strategy, it signed an investment agreement to buy an initial 19.5% stake in A.T.C. S.r.l. for €1.275 million, with the ability to increase ownership up to 51% over multiple closings for a total of €5.1 million, contingent on turnover and EBITDA milestones and maintenance of key licenses. The deal includes a put option allowing Genenta to sell back its stake if licenses are lost for at least two months or performance falls below specified thresholds, at a price equal to its total investment.
Genenta also entered a five-year, automatically renewable shareholders’ agreement with Fondazione Praexidia, a foundation linked to Italian institutional and defense figures, after its CEO donated 3,000 ADS to the foundation. They will consult on transactions subject to Italian Golden Power rules, and both parties are subject to a lock-up on their shares with defined exceptions, while the foundation receives no management powers. Separately, the company has started legal proceedings in Milan against Fondazione Enea Tech Biomedical related to a EUR 20 million convertible bond loan agreement signed in March 2025, under which Genenta has so far received EUR 7.5 million, seeking to have the agreement declared null and to obtain damages.
Genenta Science S.p.A. is launching a major strategic shift from a pure biotech focus into becoming a next‑generation industrial consolidator in Italian national‑security regulated sectors, including defense, aerospace, cybersecurity, and biosecurity. The company plans to change its corporate name to Saentra Forge S.p.A. and adopt a new Nasdaq ticker symbol SAEN, subject to shareholder approval at a meeting scheduled for March 25‑26, 2026.
Execution has started with a binding agreement to fund defense‑sector company ATC via performance‑based, staged capital increases, with a goal of obtaining a controlling position. ATC projects 2026 revenue of approximately €4.0 million and 2027 revenue around €9.0 million and expects EBITDA above €2.0 million in 2026 with a planned doubling in 2027, while operating with net cash and no bank debt.
The Praexidia Foundation, a sovereign‑aligned private foundation, has become a long‑term shareholder via a donation of shares from the CEO and entered into a shareholders’ agreement featuring consultation rights and a renewable five‑year lock‑up. Genenta is seeking to advance its cell therapy platform through partnerships rather than internally funding all trials and expects preliminary, unaudited cash, cash equivalents, and marketable securities of approximately $33 million at December 31, 2025, up from $17.7 million at June 30, 2025, primarily due to a registered direct offering.
Genenta Science S.p.A. (GNTA) reported outcomes from its Ordinary and Extraordinary Shareholders’ Meeting. Directors Armon R. Sharei, Francesco Galimi, and CEO Pierluigi Paracchi will continue on the Board, and two new directors were appointed: Miguel Maria Mutti, a senior pharma and investment banking executive, and Giacomoantonio Paracchi, a business lawyer and brother of the CEO.
Shareholders approved an amendment to Article 4 of the by-laws to extend the corporate purpose to sectors covered by Italy’s Golden Power legislation. Effectiveness is expressly conditioned on no shareholder exercising the statutory withdrawal right; a single valid withdrawal makes the amendment ineffective and does not trigger share liquidation. The withdrawal right must be exercised by registered letter within 15 days of registration of the resolution, i.e., by about November 15, 2025.
The amended by-laws were filed as Exhibit 3.1. The filing notes a recent capital increase with 4,285,715 new shares and that updated by-laws reflecting share capital will be filed within 30 days from execution.